Mode
Text Size
Log in / Sign up

Gut microbiota and inflammatory biomarkers associate with 1-year neurological recovery in cerebral hypoxia-ischemia cohort.

Gut microbiota and inflammatory biomarkers associate with 1-year neurological recovery in cerebral h…
Photo by CDC / Unsplash
Key Takeaway
Recognize these biomarker associations as predictive rather than causal, as microbiota interventions were not tested in this cohort.

This single-center cohort study evaluated 772 patients with cerebral hypoxia-ischemia to examine associations between biomarkers and 1-year neurological recovery. Participants were stratified into favorable neurological recovery (n = 538) and poor recovery (n = 234) groups based on primary outcome assessment at the single-center setting.

Analysis revealed significantly higher short-chain fatty acids, superoxide dismutase activity, and neuroprotective gene expression in the favorable recovery group (P < 0.001). Conversely, pro-inflammatory cytokines and harmful metabolites were reduced in patients with favorable outcomes (P < 0.001). Specific microbiota analysis indicated enrichment of beneficial taxa, such as Bifidobacterium longum, and depletion of pro-inflammatory species, such as Clostridium difficile.

A neural network model utilizing these markers showed stable predictive performance across validation analyses, with IL-6 emerging as a key predictive feature. Safety data regarding adverse events, serious adverse events, and discontinuations were not reported in the study. The study design is observational, meaning predictive associations are reported but causation of recovery by biomarkers is not established.

Practice relevance suggests ML-based integration of multi-modal biomarkers may facilitate clinically applicable prognostic assessment in future settings. However, this is predictive modeling rather than an interventional trial. Microbiota-targeted interventions are mentioned as a future foundation but were not tested in this study.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedMar 2026
View Original Abstract ↓
ObjectiveTo evaluate the predictive value of gut microbiota biomarkers for neurological recovery after cerebral hypoxia-ischemia and to develop a clinically oriented, validated machine learning (ML) for early outcome prediction.MethodsIn this single-center cohort study, 772 patients (2022–2024) were stratified according to 1-year neurological outcomes into favorable (n = 538) and poor recovery (n = 234) groups, gut microbiota composition, microbial metabolites, systemic inflammatory and oxidative stress markers, and selected gene expression profiles were assessed using blood and fecal samples. Microbial profiling was assessed via 16S rRNA sequencing and whole-genome sequencing. LASSO regression, random forest (RF), and neural networks models were constructed and evaluated using internal validation strategies and augmented with publicly available datasets.ResultsPatients with favorable neurological recovery exhibited significantly higher levels of short-chain fatty acids, increased superoxide dismutase activity, and upregulated neuroprotective gene expression, along with reduced pro-inflammatory cytokines and harmful metabolites (all P < 0.001). Microbiota analysis demonstrated enrichment of beneficial taxa (e.g., Bifidobacterium longum) and depletion of pro-inflammatory species (e.g., Clostridium difficile). Across ML approaches, IL-6 consistently emerged as a key predictive feature, with RF confirmed its prelative importance. The neural network model showed stable predictive performance across validation analyses, indicating robustness for high-dimensional biomarker integration.ConclusionGut microbiota–associated biomarkers, when combined with systemic inflammatory indicators such as IL-6, enable robust early prediction of neurological recovery following cerebral hypoxia–ischemia. ML-based integration of multi-modal biomarkers may facilitate clinically applicable prognostic assessment, while also providing a foundation for future investigations into microbiota-targeted interventions.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.